

# Periotherapia Co., Ltd. (For Investor and Business partner)

## Company Overview

Name: Periotherapia Co., Ltd.  
 Founded: October 2, 2017  
 Business: Drug discovery for refractory diseases such as treatment-resistant breast cancer

Fundraising (Cumulative amount) :

**¥1.87B (\$12.5M)**

Next Fundraising (Scheduled for December 2025):


Planned total amount is

**¥2.5B (\$16.7M) / Pre-Val ¥4B (\$26.7M)**

\$1 = ¥150

## Genre of Technology

- We are focusing Periostin splicing variants (Pathological Periostin).
- Our **antibodies** bind to only Exon 17 or 21 on Pathological Periostin.



- Pathological Periostin creates tumor microenvironment (suitable for cancer cells) and induces resistance against anticancer drugs.

## Comparison

	Periotherapia mAbs (PT0101/PT0201)	Anti-Periostin (Pan) mAb
Target	Pathological periostin	Pan periostin
Distribution	restricted	systemic
Safety*	<b>Low</b>	High
Efficacy	<b>High</b>	Low**

- \* Inferred from periostin knockout mouse phenotype
- \*\* In-house generation of similar antibodies (pAb) from information contained in patents
- Our abs are safer than other abs inhibiting all Periostin variants including physiological periostin.

Code: PT0101

## Indication /Lead compound

Indication: **Metastatic/recurrent HER2-negative Breast Cancer**


**(Unmet medical needs , Especially common in young women under 40 )**

◆ **This project is supported by AMED grant, max. ¥6B (\$40M).**

AMED: Japan Agency for Medical Research and Development

Ready for P1 trials (Japan)

- GLP tox ✓, GMP drug substance ✓PMDA consultation ✓



**ADC is a potential combination drug**

## Standing Data: Combination therapy with Paclitaxel

